Natalie Serkova
Concepts (676)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Magnetic Resonance Spectroscopy | 35 | 2014 | 508 | 3.160 |
Why?
| Cyclosporine | 18 | 2012 | 173 | 2.790 |
Why?
| Immunosuppressive Agents | 21 | 2013 | 681 | 2.320 |
Why?
| Sirolimus | 17 | 2013 | 195 | 2.030 |
Why?
| Magnetic Resonance Imaging | 24 | 2020 | 3174 | 1.920 |
Why?
| Pyrimidines | 8 | 2017 | 382 | 1.420 |
Why?
| Piperazines | 6 | 2009 | 316 | 1.370 |
Why?
| Metabolomics | 11 | 2021 | 550 | 1.320 |
Why?
| Glucose | 14 | 2021 | 953 | 1.230 |
Why?
| Contrast Media | 6 | 2017 | 373 | 1.190 |
Why?
| Energy Metabolism | 13 | 2019 | 767 | 1.140 |
Why?
| Brain | 13 | 2020 | 2490 | 1.140 |
Why?
| Antineoplastic Agents | 15 | 2022 | 1974 | 1.140 |
Why?
| Biomarkers | 14 | 2019 | 3588 | 1.060 |
Why?
| Neoplasms | 14 | 2017 | 2179 | 1.030 |
Why?
| Liver | 12 | 2020 | 1816 | 1.020 |
Why?
| Drug Resistance, Neoplasm | 6 | 2017 | 671 | 0.980 |
Why?
| Animals | 95 | 2023 | 33381 | 0.940 |
Why?
| Neoplasms, Experimental | 3 | 2020 | 158 | 0.920 |
Why?
| Reperfusion Injury | 11 | 2014 | 276 | 0.810 |
Why?
| Biomarkers, Tumor | 10 | 2020 | 1059 | 0.770 |
Why?
| Multimodal Imaging | 1 | 2020 | 100 | 0.740 |
Why?
| Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 21 | 0.720 |
Why?
| Protein Kinase Inhibitors | 10 | 2018 | 811 | 0.720 |
Why?
| Rats | 29 | 2015 | 5392 | 0.700 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2014 | 93 | 0.680 |
Why?
| Ferrosoferric Oxide | 3 | 2019 | 26 | 0.680 |
Why?
| Metabolome | 5 | 2019 | 296 | 0.660 |
Why?
| Cell Line, Tumor | 25 | 2023 | 2851 | 0.650 |
Why?
| Nanoparticles | 4 | 2017 | 325 | 0.630 |
Why?
| Ischemic Preconditioning | 2 | 2009 | 29 | 0.630 |
Why?
| Hypoxia | 6 | 2015 | 963 | 0.570 |
Why?
| Fusion Proteins, bcr-abl | 5 | 2015 | 61 | 0.560 |
Why?
| Phospholipids | 7 | 2010 | 208 | 0.550 |
Why?
| Everolimus | 12 | 2013 | 64 | 0.540 |
Why?
| Aging | 5 | 2020 | 1670 | 0.540 |
Why?
| Rats, Wistar | 11 | 2010 | 399 | 0.530 |
Why?
| Mice | 45 | 2023 | 15520 | 0.530 |
Why?
| Glutathione | 9 | 2023 | 324 | 0.520 |
Why?
| Body Fluids | 5 | 2019 | 62 | 0.510 |
Why?
| Inositol | 4 | 2021 | 26 | 0.500 |
Why?
| Glutamine | 6 | 2013 | 88 | 0.500 |
Why?
| Epilepsy, Post-Traumatic | 1 | 2013 | 3 | 0.480 |
Why?
| Organ Specificity | 4 | 2013 | 278 | 0.480 |
Why?
| Brain Injuries | 3 | 2014 | 484 | 0.470 |
Why?
| Nephritis | 1 | 2013 | 30 | 0.470 |
Why?
| Mitochondria | 7 | 2014 | 786 | 0.470 |
Why?
| Positron-Emission Tomography | 10 | 2020 | 298 | 0.470 |
Why?
| Lupus Nephritis | 2 | 2011 | 55 | 0.460 |
Why?
| Imatinib Mesylate | 7 | 2014 | 64 | 0.440 |
Why?
| Leukemia | 2 | 2018 | 208 | 0.430 |
Why?
| Disease Models, Animal | 16 | 2023 | 3730 | 0.420 |
Why?
| Apoptosis | 14 | 2022 | 2484 | 0.420 |
Why?
| Placenta | 3 | 2009 | 639 | 0.420 |
Why?
| Humans | 71 | 2023 | 118974 | 0.410 |
Why?
| Metabolism | 3 | 2017 | 39 | 0.410 |
Why?
| Reactive Oxygen Species | 5 | 2013 | 576 | 0.400 |
Why?
| Oxidative Stress | 5 | 2010 | 1178 | 0.400 |
Why?
| Drug Monitoring | 3 | 2013 | 187 | 0.400 |
Why?
| Time Factors | 12 | 2013 | 6412 | 0.390 |
Why?
| Benzamides | 6 | 2009 | 176 | 0.390 |
Why?
| Kidney | 7 | 2023 | 1353 | 0.390 |
Why?
| Cerebellar Neoplasms | 2 | 2023 | 135 | 0.380 |
Why?
| Seizures | 1 | 2013 | 345 | 0.380 |
Why?
| Astrocytes | 4 | 2015 | 177 | 0.380 |
Why?
| Medulloblastoma | 2 | 2023 | 177 | 0.380 |
Why?
| Liver Diseases | 2 | 2010 | 282 | 0.370 |
Why?
| Kidney Diseases | 2 | 2020 | 439 | 0.360 |
Why?
| Diagnostic Imaging | 2 | 2011 | 294 | 0.360 |
Why?
| Molecular Targeted Therapy | 2 | 2017 | 356 | 0.350 |
Why?
| Molecular Probes | 1 | 2009 | 30 | 0.350 |
Why?
| Cell Proliferation | 13 | 2022 | 2275 | 0.350 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 246 | 0.350 |
Why?
| Glucose Transporter Type 1 | 1 | 2009 | 42 | 0.340 |
Why?
| Prostatic Neoplasms | 5 | 2016 | 940 | 0.330 |
Why?
| Liver Transplantation | 2 | 2007 | 847 | 0.330 |
Why?
| Silymarin | 4 | 2016 | 193 | 0.330 |
Why?
| Complement C3b | 2 | 2023 | 30 | 0.330 |
Why?
| Lactic Acid | 7 | 2013 | 282 | 0.330 |
Why?
| Spermine | 1 | 2008 | 28 | 0.330 |
Why?
| K562 Cells | 4 | 2009 | 73 | 0.320 |
Why?
| Citric Acid | 1 | 2008 | 34 | 0.320 |
Why?
| Adaptation, Physiological | 2 | 2009 | 502 | 0.320 |
Why?
| Xenograft Model Antitumor Assays | 9 | 2019 | 740 | 0.310 |
Why?
| Graft Rejection | 5 | 2010 | 555 | 0.310 |
Why?
| Tomography, X-Ray Computed | 3 | 2020 | 2436 | 0.310 |
Why?
| Hibernation | 2 | 2014 | 77 | 0.310 |
Why?
| Drug Design | 2 | 2007 | 160 | 0.310 |
Why?
| Kidney Transplantation | 4 | 2010 | 585 | 0.300 |
Why?
| Head and Neck Neoplasms | 3 | 2019 | 471 | 0.300 |
Why?
| Prostate | 1 | 2008 | 158 | 0.300 |
Why?
| Altitude | 3 | 2009 | 422 | 0.300 |
Why?
| Creatine | 3 | 2021 | 56 | 0.290 |
Why?
| Choline | 2 | 2009 | 109 | 0.290 |
Why?
| Colorectal Neoplasms | 4 | 2018 | 628 | 0.290 |
Why?
| Liver Failure | 1 | 2007 | 85 | 0.290 |
Why?
| Dietary Supplements | 3 | 2023 | 467 | 0.280 |
Why?
| Male | 45 | 2022 | 57801 | 0.280 |
Why?
| Pneumonia | 2 | 2011 | 592 | 0.280 |
Why?
| Drug Therapy | 1 | 2006 | 76 | 0.280 |
Why?
| Signal Transduction | 11 | 2019 | 4709 | 0.280 |
Why?
| Adenosine Triphosphate | 5 | 2009 | 439 | 0.270 |
Why?
| Brain Injuries, Traumatic | 2 | 2023 | 318 | 0.270 |
Why?
| Brain Neoplasms | 4 | 2020 | 1022 | 0.270 |
Why?
| Sex Characteristics | 1 | 2010 | 671 | 0.270 |
Why?
| Glioma | 3 | 2020 | 306 | 0.270 |
Why?
| Interleukin-1beta | 1 | 2008 | 379 | 0.270 |
Why?
| fms-Like Tyrosine Kinase 3 | 2 | 2016 | 42 | 0.270 |
Why?
| Blotting, Western | 6 | 2019 | 1194 | 0.260 |
Why?
| Neovascularization, Pathologic | 4 | 2018 | 287 | 0.260 |
Why?
| Macrolides | 2 | 2013 | 57 | 0.260 |
Why?
| Protein Kinases | 2 | 2004 | 310 | 0.250 |
Why?
| Carcinoma, Hepatocellular | 2 | 2020 | 227 | 0.250 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2022 | 455 | 0.250 |
Why?
| Protein-Tyrosine Kinases | 3 | 2014 | 407 | 0.250 |
Why?
| Organ Transplantation | 2 | 2004 | 165 | 0.250 |
Why?
| Sepsis | 4 | 2013 | 531 | 0.250 |
Why?
| Neurotoxicity Syndromes | 1 | 2004 | 15 | 0.240 |
Why?
| Obesity | 3 | 2006 | 2746 | 0.240 |
Why?
| Glycolysis | 4 | 2010 | 224 | 0.240 |
Why?
| Rats, Sprague-Dawley | 9 | 2015 | 2478 | 0.240 |
Why?
| Cell Transformation, Neoplastic | 3 | 2015 | 317 | 0.240 |
Why?
| Drug Interactions | 5 | 2012 | 352 | 0.240 |
Why?
| Myocardium | 2 | 2013 | 970 | 0.240 |
Why?
| Lung Transplantation | 3 | 2000 | 263 | 0.230 |
Why?
| Chromatography, High Pressure Liquid | 4 | 2009 | 490 | 0.230 |
Why?
| Autolysis | 1 | 2003 | 3 | 0.230 |
Why?
| Myocardial Reperfusion Injury | 1 | 2003 | 105 | 0.230 |
Why?
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 1167 | 0.220 |
Why?
| Deoxycytidine | 2 | 2017 | 136 | 0.220 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2008 | 1171 | 0.220 |
Why?
| Fatty Liver | 1 | 2005 | 253 | 0.220 |
Why?
| Glomerulonephritis | 1 | 2023 | 60 | 0.220 |
Why?
| Phosphates | 2 | 2001 | 167 | 0.220 |
Why?
| Autophagy | 2 | 2018 | 315 | 0.210 |
Why?
| Colonic Neoplasms | 3 | 2013 | 224 | 0.210 |
Why?
| Carbon Isotopes | 3 | 2009 | 115 | 0.210 |
Why?
| In Vitro Techniques | 5 | 2016 | 1094 | 0.210 |
Why?
| Antineoplastic Agents, Phytogenic | 2 | 2013 | 180 | 0.210 |
Why?
| Specimen Handling | 1 | 2003 | 165 | 0.200 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 65 | 0.200 |
Why?
| Blood-Brain Barrier | 2 | 2013 | 108 | 0.200 |
Why?
| Mice, Nude | 8 | 2016 | 663 | 0.200 |
Why?
| Chemoradiotherapy | 2 | 2019 | 200 | 0.200 |
Why?
| Image Processing, Computer-Assisted | 3 | 2019 | 709 | 0.200 |
Why?
| Lung | 8 | 2018 | 3664 | 0.200 |
Why?
| Hydroxamic Acids | 2 | 2011 | 80 | 0.200 |
Why?
| Photoacoustic Techniques | 1 | 2020 | 5 | 0.200 |
Why?
| Radiation Tolerance | 1 | 2022 | 98 | 0.200 |
Why?
| Rhabdoid Tumor | 1 | 2022 | 80 | 0.190 |
Why?
| Magnetite Nanoparticles | 2 | 2011 | 28 | 0.190 |
Why?
| Tendinopathy | 1 | 2021 | 34 | 0.190 |
Why?
| Gene Expression Regulation | 4 | 2019 | 2445 | 0.190 |
Why?
| Dose-Response Relationship, Drug | 8 | 2012 | 1945 | 0.190 |
Why?
| TOR Serine-Threonine Kinases | 5 | 2018 | 369 | 0.190 |
Why?
| Anticarcinogenic Agents | 2 | 2011 | 68 | 0.190 |
Why?
| Heat-Shock Proteins | 3 | 2006 | 129 | 0.190 |
Why?
| Perfusion | 3 | 2009 | 153 | 0.190 |
Why?
| Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 105 | 0.190 |
Why?
| Mass Spectrometry | 4 | 2011 | 681 | 0.180 |
Why?
| Anterior Cruciate Ligament Injuries | 1 | 2022 | 147 | 0.180 |
Why?
| Mammary Glands, Animal | 2 | 2014 | 124 | 0.180 |
Why?
| Insulin Resistance | 2 | 2019 | 1180 | 0.180 |
Why?
| Camptothecin | 2 | 2013 | 100 | 0.180 |
Why?
| Osteoarthritis | 1 | 2022 | 176 | 0.180 |
Why?
| Transcriptional Elongation Factors | 1 | 2020 | 33 | 0.180 |
Why?
| Polycomb Repressive Complex 1 | 1 | 2020 | 51 | 0.180 |
Why?
| Particle Accelerators | 1 | 2019 | 9 | 0.180 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1390 | 0.180 |
Why?
| Scavenger Receptors, Class A | 1 | 2019 | 9 | 0.180 |
Why?
| Electromagnetic Phenomena | 1 | 2019 | 23 | 0.180 |
Why?
| Complement Factor H | 1 | 2020 | 61 | 0.180 |
Why?
| Lactation | 2 | 2014 | 160 | 0.180 |
Why?
| Histone Deacetylase Inhibitors | 2 | 2011 | 200 | 0.180 |
Why?
| Heart | 1 | 2003 | 631 | 0.180 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 2019 | 74 | 0.180 |
Why?
| Brain Chemistry | 1 | 2000 | 119 | 0.180 |
Why?
| Fatty Acids | 2 | 2015 | 407 | 0.180 |
Why?
| Endoplasmic Reticulum Stress | 3 | 2014 | 97 | 0.170 |
Why?
| DNA Repair | 1 | 2021 | 198 | 0.170 |
Why?
| Infratentorial Neoplasms | 1 | 2019 | 50 | 0.170 |
Why?
| Macrophages, Peritoneal | 1 | 2019 | 96 | 0.170 |
Why?
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 115 | 0.170 |
Why?
| Fluorodeoxyglucose F18 | 2 | 2021 | 131 | 0.170 |
Why?
| Precursor Cells, B-Lymphoid | 2 | 2017 | 33 | 0.170 |
Why?
| Tumor Microenvironment | 2 | 2019 | 454 | 0.170 |
Why?
| Receptor, EphB4 | 1 | 2019 | 29 | 0.170 |
Why?
| Ephrin-B2 | 1 | 2019 | 42 | 0.170 |
Why?
| Lipogenesis | 2 | 2016 | 66 | 0.170 |
Why?
| Angiogenesis Inhibitors | 2 | 2011 | 219 | 0.170 |
Why?
| Whey Proteins | 1 | 2018 | 5 | 0.170 |
Why?
| Phosphocreatine | 3 | 2004 | 37 | 0.160 |
Why?
| Neoplasm Proteins | 2 | 2020 | 401 | 0.160 |
Why?
| Smad4 Protein | 1 | 2018 | 37 | 0.160 |
Why?
| Glucose Clamp Technique | 1 | 2019 | 194 | 0.160 |
Why?
| Histones | 2 | 2020 | 552 | 0.160 |
Why?
| Salivary Gland Neoplasms | 1 | 2018 | 32 | 0.160 |
Why?
| Tracheal Stenosis | 1 | 2018 | 23 | 0.160 |
Why?
| Anilides | 1 | 2018 | 69 | 0.160 |
Why?
| Polyenes | 1 | 1997 | 8 | 0.160 |
Why?
| Female | 28 | 2022 | 61565 | 0.160 |
Why?
| Proto-Oncogene Proteins p21(ras) | 3 | 2013 | 237 | 0.160 |
Why?
| Liver Neoplasms | 2 | 2020 | 527 | 0.160 |
Why?
| Rats, Zucker | 3 | 2006 | 34 | 0.160 |
Why?
| Ependymoma | 1 | 2019 | 169 | 0.150 |
Why?
| Mucin-1 | 1 | 2017 | 18 | 0.150 |
Why?
| Fibroblasts | 2 | 2016 | 842 | 0.150 |
Why?
| Macrophages | 3 | 2019 | 1324 | 0.150 |
Why?
| Pancreatic Neoplasms | 2 | 2017 | 734 | 0.150 |
Why?
| Kinetics | 3 | 2009 | 1624 | 0.150 |
Why?
| Neuroprotective Agents | 1 | 2018 | 111 | 0.150 |
Why?
| Acute Lung Injury | 2 | 2011 | 310 | 0.150 |
Why?
| Folic Acid Deficiency | 1 | 2017 | 48 | 0.150 |
Why?
| Cells, Cultured | 6 | 2019 | 4077 | 0.150 |
Why?
| PTEN Phosphohydrolase | 1 | 2018 | 143 | 0.150 |
Why?
| Lactates | 3 | 2006 | 87 | 0.150 |
Why?
| Drug Synergism | 5 | 2013 | 339 | 0.150 |
Why?
| Adenosine Diphosphate | 2 | 2009 | 88 | 0.150 |
Why?
| Blood Glucose | 4 | 2019 | 1939 | 0.150 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 62 | 0.140 |
Why?
| Quinazolines | 2 | 2008 | 245 | 0.140 |
Why?
| Glucosephosphate Dehydrogenase | 1 | 2016 | 41 | 0.140 |
Why?
| Tissue Extracts | 2 | 2009 | 20 | 0.140 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2016 | 49 | 0.140 |
Why?
| Heme Oxygenase (Decyclizing) | 2 | 2013 | 20 | 0.140 |
Why?
| Folic Acid | 1 | 2017 | 161 | 0.140 |
Why?
| Hematopoiesis | 1 | 2017 | 175 | 0.140 |
Why?
| Inflammation Mediators | 1 | 2019 | 502 | 0.140 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 86 | 0.140 |
Why?
| Pyrazoles | 2 | 2010 | 363 | 0.140 |
Why?
| Transcription Factors | 5 | 2014 | 1570 | 0.140 |
Why?
| Brain Concussion | 1 | 2023 | 470 | 0.140 |
Why?
| Flow Cytometry | 2 | 2010 | 1085 | 0.140 |
Why?
| Alcohol Oxidoreductases | 1 | 2016 | 57 | 0.140 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 4 | 2011 | 240 | 0.140 |
Why?
| Creatinine | 4 | 2005 | 491 | 0.140 |
Why?
| Lipid Peroxidation | 3 | 2006 | 156 | 0.140 |
Why?
| Familial Primary Pulmonary Hypertension | 1 | 2016 | 193 | 0.140 |
Why?
| Neuroglia | 1 | 1996 | 157 | 0.130 |
Why?
| Lipid Metabolism | 4 | 2019 | 477 | 0.130 |
Why?
| Hypothermia, Induced | 2 | 2006 | 68 | 0.130 |
Why?
| Hernias, Diaphragmatic, Congenital | 1 | 2018 | 189 | 0.130 |
Why?
| Paracrine Communication | 1 | 2015 | 57 | 0.130 |
Why?
| Nuclear Proteins | 2 | 2023 | 597 | 0.130 |
Why?
| Methylamines | 2 | 2005 | 32 | 0.130 |
Why?
| Oligomycins | 1 | 2014 | 8 | 0.130 |
Why?
| Indoles | 2 | 2015 | 316 | 0.130 |
Why?
| Radiography | 2 | 2008 | 861 | 0.130 |
Why?
| Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 18 | 0.130 |
Why?
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 420 | 0.130 |
Why?
| Homeostasis | 1 | 2018 | 594 | 0.130 |
Why?
| Pentacyclic Triterpenes | 1 | 2014 | 13 | 0.130 |
Why?
| Fatty Acids, Unsaturated | 2 | 2005 | 86 | 0.130 |
Why?
| Pyridines | 1 | 2018 | 440 | 0.130 |
Why?
| Ferric Compounds | 1 | 2014 | 39 | 0.130 |
Why?
| Hypertension, Pulmonary | 2 | 2016 | 1794 | 0.120 |
Why?
| Fatty Acid Synthase, Type I | 1 | 2014 | 5 | 0.120 |
Why?
| Models, Animal | 2 | 2009 | 363 | 0.120 |
Why?
| ras Proteins | 2 | 2013 | 141 | 0.120 |
Why?
| Rats, Inbred Lew | 4 | 2010 | 87 | 0.120 |
Why?
| Lipoxygenase Inhibitors | 1 | 2014 | 36 | 0.120 |
Why?
| Convulsants | 1 | 2013 | 6 | 0.120 |
Why?
| Leukotrienes | 1 | 2014 | 35 | 0.120 |
Why?
| Dextrans | 2 | 2014 | 74 | 0.120 |
Why?
| Kainic Acid | 1 | 2013 | 32 | 0.120 |
Why?
| Fetal Growth Retardation | 1 | 2019 | 468 | 0.120 |
Why?
| Prognosis | 4 | 2017 | 3443 | 0.120 |
Why?
| NAD | 2 | 2004 | 67 | 0.120 |
Why?
| Propranolol | 1 | 2013 | 54 | 0.120 |
Why?
| Urothelium | 1 | 2013 | 33 | 0.120 |
Why?
| Brain Edema | 1 | 2013 | 61 | 0.120 |
Why?
| Azoxymethane | 1 | 2013 | 17 | 0.120 |
Why?
| Unfolded Protein Response | 1 | 2013 | 46 | 0.120 |
Why?
| Mice, Inbred BALB C | 4 | 2019 | 1206 | 0.110 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 90 | 0.110 |
Why?
| Cell Survival | 4 | 2016 | 1047 | 0.110 |
Why?
| Triple Negative Breast Neoplasms | 1 | 2015 | 164 | 0.110 |
Why?
| Insulin | 3 | 2019 | 2162 | 0.110 |
Why?
| Pregnancy | 6 | 2019 | 5691 | 0.110 |
Why?
| Phosphorylation | 3 | 2013 | 1633 | 0.110 |
Why?
| Grape Seed Extract | 1 | 2013 | 41 | 0.110 |
Why?
| Estrogens | 1 | 2015 | 328 | 0.110 |
Why?
| Feasibility Studies | 2 | 2019 | 749 | 0.110 |
Why?
| Equipment Design | 2 | 2019 | 519 | 0.110 |
Why?
| Phytic Acid | 1 | 2012 | 44 | 0.110 |
Why?
| Tumor Cells, Cultured | 3 | 2019 | 874 | 0.110 |
Why?
| Severity of Illness Index | 2 | 2013 | 2674 | 0.110 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 982 | 0.110 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 103 | 0.110 |
Why?
| DNA-Binding Proteins | 3 | 2016 | 1346 | 0.110 |
Why?
| Thiophenes | 1 | 2013 | 106 | 0.110 |
Why?
| Metabolic Diseases | 1 | 2013 | 103 | 0.110 |
Why?
| Reference Values | 3 | 2019 | 774 | 0.110 |
Why?
| Quinolines | 1 | 2013 | 128 | 0.100 |
Why?
| Shock, Hemorrhagic | 1 | 2014 | 206 | 0.100 |
Why?
| Image Enhancement | 2 | 2010 | 181 | 0.100 |
Why?
| Radionuclide Imaging | 1 | 2012 | 124 | 0.100 |
Why?
| Mice, Transgenic | 6 | 2015 | 2025 | 0.100 |
Why?
| Treatment Outcome | 8 | 2016 | 9342 | 0.100 |
Why?
| Sarcoma | 1 | 2013 | 137 | 0.100 |
Why?
| Glioblastoma | 1 | 2014 | 262 | 0.100 |
Why?
| Electroencephalography | 1 | 2013 | 387 | 0.100 |
Why?
| Temperature | 3 | 2014 | 622 | 0.100 |
Why?
| Isotope Labeling | 1 | 2012 | 76 | 0.100 |
Why?
| HSP70 Heat-Shock Proteins | 3 | 2010 | 74 | 0.100 |
Why?
| Reproducibility of Results | 5 | 2019 | 2874 | 0.100 |
Why?
| Adult | 10 | 2013 | 31512 | 0.100 |
Why?
| Tandem Mass Spectrometry | 2 | 2014 | 421 | 0.100 |
Why?
| Proto-Oncogene Proteins | 2 | 2013 | 618 | 0.100 |
Why?
| Urinary Bladder | 1 | 2013 | 180 | 0.100 |
Why?
| Calcineurin | 1 | 2012 | 95 | 0.100 |
Why?
| Adrenergic beta-Antagonists | 1 | 2013 | 301 | 0.100 |
Why?
| Antibodies, Monoclonal | 3 | 2023 | 1284 | 0.100 |
Why?
| Mice, Inbred NOD | 3 | 2019 | 574 | 0.100 |
Why?
| Proteasome Inhibitors | 1 | 2011 | 44 | 0.100 |
Why?
| Tissue Distribution | 2 | 2003 | 334 | 0.100 |
Why?
| Boronic Acids | 1 | 2011 | 35 | 0.100 |
Why?
| Tacrolimus | 1 | 2012 | 151 | 0.100 |
Why?
| Nucleotides | 2 | 2017 | 112 | 0.100 |
Why?
| Models, Biological | 5 | 2013 | 1715 | 0.100 |
Why?
| Benzimidazoles | 1 | 2011 | 140 | 0.100 |
Why?
| Sciuridae | 2 | 2014 | 145 | 0.100 |
Why?
| Pyrazines | 1 | 2011 | 72 | 0.090 |
Why?
| Phosphatidylinositol 3-Kinases | 3 | 2018 | 341 | 0.090 |
Why?
| Hydroxybutyrates | 2 | 2010 | 11 | 0.090 |
Why?
| Complement C3-C5 Convertases | 1 | 2010 | 19 | 0.090 |
Why?
| Protease Inhibitors | 1 | 2011 | 102 | 0.090 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2010 | 165 | 0.090 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2016 | 532 | 0.090 |
Why?
| Cricetulus | 1 | 2010 | 98 | 0.090 |
Why?
| CHO Cells | 1 | 2010 | 143 | 0.090 |
Why?
| Mice, Knockout | 5 | 2020 | 2680 | 0.090 |
Why?
| Heart Ventricles | 1 | 2015 | 727 | 0.090 |
Why?
| TRPP Cation Channels | 1 | 2010 | 63 | 0.090 |
Why?
| Cricetinae | 1 | 2010 | 262 | 0.090 |
Why?
| Fatty Acids, Monounsaturated | 2 | 2010 | 46 | 0.090 |
Why?
| Epigenomics | 2 | 2020 | 107 | 0.090 |
Why?
| Drug Delivery Systems | 2 | 2017 | 306 | 0.090 |
Why?
| Cognition Disorders | 1 | 2014 | 529 | 0.090 |
Why?
| Ribose | 1 | 2009 | 18 | 0.090 |
Why?
| Neoplasm Transplantation | 3 | 2019 | 245 | 0.090 |
Why?
| ErbB Receptors | 2 | 2015 | 569 | 0.090 |
Why?
| Cysts | 1 | 2010 | 93 | 0.090 |
Why?
| Intestine, Small | 1 | 2010 | 131 | 0.090 |
Why?
| Dinoprost | 1 | 2009 | 31 | 0.090 |
Why?
| Deoxyglucose | 1 | 2009 | 46 | 0.090 |
Why?
| Analysis of Variance | 2 | 2010 | 1293 | 0.090 |
Why?
| Alanine | 2 | 2013 | 102 | 0.090 |
Why?
| Cell Extracts | 1 | 2009 | 17 | 0.090 |
Why?
| Percussion | 1 | 2008 | 3 | 0.090 |
Why?
| RNA, Neoplasm | 1 | 2009 | 77 | 0.090 |
Why?
| Sulfonamides | 2 | 2011 | 445 | 0.080 |
Why?
| History, 21st Century | 1 | 2009 | 170 | 0.080 |
Why?
| Mutation | 3 | 2020 | 3457 | 0.080 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 135 | 0.080 |
Why?
| Surgical Equipment | 1 | 2008 | 13 | 0.080 |
Why?
| Systems Biology | 1 | 2009 | 57 | 0.080 |
Why?
| History, 20th Century | 1 | 2009 | 281 | 0.080 |
Why?
| Oxidation-Reduction | 3 | 2016 | 940 | 0.080 |
Why?
| Neurons | 1 | 1996 | 1345 | 0.080 |
Why?
| Receptor, ErbB-3 | 1 | 2008 | 42 | 0.080 |
Why?
| Macaca fascicularis | 4 | 2000 | 53 | 0.080 |
Why?
| Oxygen | 2 | 2010 | 854 | 0.080 |
Why?
| Complement C3d | 2 | 2023 | 60 | 0.080 |
Why?
| Critical Illness | 2 | 2011 | 662 | 0.080 |
Why?
| Fluorouracil | 1 | 2008 | 151 | 0.080 |
Why?
| Body Weight | 4 | 2012 | 934 | 0.080 |
Why?
| Disease Progression | 5 | 2018 | 2490 | 0.080 |
Why?
| Lymphocytes | 1 | 2009 | 347 | 0.080 |
Why?
| Protein Transport | 1 | 2009 | 412 | 0.080 |
Why?
| Area Under Curve | 1 | 2008 | 296 | 0.080 |
Why?
| Mice, Inbred C57BL | 5 | 2018 | 4908 | 0.080 |
Why?
| Triglycerides | 2 | 2010 | 519 | 0.080 |
Why?
| Oxidative Phosphorylation | 2 | 2005 | 156 | 0.070 |
Why?
| DNA | 2 | 2009 | 1388 | 0.070 |
Why?
| Heart-Assist Devices | 1 | 2013 | 485 | 0.070 |
Why?
| X-Ray Microtomography | 2 | 2021 | 79 | 0.070 |
Why?
| Heterografts | 2 | 2019 | 130 | 0.070 |
Why?
| Medical Oncology | 1 | 2009 | 229 | 0.070 |
Why?
| Tritium | 1 | 2006 | 70 | 0.070 |
Why?
| Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 209 | 0.070 |
Why?
| Age Factors | 2 | 2011 | 2995 | 0.070 |
Why?
| ROC Curve | 1 | 2008 | 473 | 0.070 |
Why?
| Chromatin | 2 | 2020 | 441 | 0.070 |
Why?
| MicroRNAs | 1 | 2013 | 637 | 0.070 |
Why?
| Body Temperature | 1 | 2007 | 215 | 0.070 |
Why?
| Leukocytes, Mononuclear | 1 | 2009 | 509 | 0.070 |
Why?
| Piperidines | 1 | 2007 | 171 | 0.070 |
Why?
| Maximum Tolerated Dose | 3 | 2013 | 185 | 0.070 |
Why?
| Up-Regulation | 2 | 2006 | 872 | 0.070 |
Why?
| Heat-Shock Response | 1 | 2006 | 59 | 0.070 |
Why?
| Alcohol Drinking | 1 | 2012 | 652 | 0.070 |
Why?
| Receptor, ErbB-2 | 1 | 2008 | 320 | 0.070 |
Why?
| Nitrogen | 1 | 2007 | 154 | 0.070 |
Why?
| Liver Failure, Acute | 1 | 2006 | 63 | 0.070 |
Why?
| Survival Rate | 3 | 2019 | 1720 | 0.070 |
Why?
| Deuterium | 1 | 2005 | 78 | 0.070 |
Why?
| Lung Injury | 1 | 2008 | 210 | 0.070 |
Why?
| Allantoin | 1 | 2005 | 3 | 0.070 |
Why?
| Betaine | 1 | 2005 | 64 | 0.070 |
Why?
| Glutamic Acid | 2 | 2010 | 224 | 0.060 |
Why?
| Methionine | 1 | 2005 | 145 | 0.060 |
Why?
| Seasons | 1 | 2007 | 461 | 0.060 |
Why?
| Inflammation | 3 | 2015 | 2566 | 0.060 |
Why?
| Reference Standards | 2 | 2019 | 176 | 0.060 |
Why?
| Glutamates | 1 | 2004 | 60 | 0.060 |
Why?
| Aged | 5 | 2013 | 19657 | 0.060 |
Why?
| Lipids | 2 | 2021 | 607 | 0.060 |
Why?
| Hot Temperature | 1 | 2006 | 334 | 0.060 |
Why?
| Mitochondrial Encephalomyopathies | 1 | 2004 | 8 | 0.060 |
Why?
| Heart Rate | 2 | 2009 | 729 | 0.060 |
Why?
| Cholesterol | 1 | 2005 | 373 | 0.060 |
Why?
| Biological Transport | 2 | 2015 | 382 | 0.060 |
Why?
| Free Radical Scavengers | 1 | 2004 | 88 | 0.060 |
Why?
| Dacarbazine | 2 | 2014 | 102 | 0.060 |
Why?
| Gene Expression Profiling | 3 | 2019 | 1597 | 0.060 |
Why?
| Hypoxia-Ischemia, Brain | 1 | 2004 | 26 | 0.060 |
Why?
| HSP72 Heat-Shock Proteins | 1 | 2003 | 29 | 0.060 |
Why?
| Calcineurin Inhibitors | 1 | 2003 | 61 | 0.060 |
Why?
| Coronary Circulation | 1 | 2003 | 121 | 0.060 |
Why?
| Proteins | 1 | 2009 | 938 | 0.060 |
Why?
| Injections, Intravenous | 1 | 2003 | 210 | 0.060 |
Why?
| RNA, Small Interfering | 2 | 2016 | 564 | 0.060 |
Why?
| Cardiac Output | 1 | 2003 | 147 | 0.060 |
Why?
| Mitochondria, Liver | 1 | 2003 | 70 | 0.060 |
Why?
| Gliosis | 1 | 2023 | 35 | 0.060 |
Why?
| Mitochondria, Heart | 1 | 2003 | 76 | 0.060 |
Why?
| Acetylcysteine | 1 | 2004 | 148 | 0.060 |
Why?
| Tyrosine | 1 | 2023 | 233 | 0.060 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2023 | 145 | 0.060 |
Why?
| Necrosis | 3 | 2010 | 230 | 0.060 |
Why?
| Wounds and Injuries | 1 | 2010 | 772 | 0.050 |
Why?
| Adenocarcinoma | 1 | 2009 | 812 | 0.050 |
Why?
| Models, Cardiovascular | 1 | 2003 | 180 | 0.050 |
Why?
| Rupture | 1 | 2022 | 105 | 0.050 |
Why?
| Reperfusion | 1 | 2002 | 43 | 0.050 |
Why?
| Middle Aged | 6 | 2016 | 27617 | 0.050 |
Why?
| Anterior Cruciate Ligament | 1 | 2022 | 89 | 0.050 |
Why?
| Tumor Burden | 2 | 2014 | 274 | 0.050 |
Why?
| Oxaloacetic Acid | 1 | 2001 | 3 | 0.050 |
Why?
| Uric Acid | 1 | 2005 | 354 | 0.050 |
Why?
| AMP-Activated Protein Kinases | 2 | 2013 | 178 | 0.050 |
Why?
| Aspartic Acid | 1 | 2001 | 86 | 0.050 |
Why?
| Succinic Acid | 2 | 2013 | 46 | 0.050 |
Why?
| Teratoma | 1 | 2022 | 92 | 0.050 |
Why?
| Microsomes, Liver | 1 | 2001 | 59 | 0.050 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 404 | 0.050 |
Why?
| Tibia | 1 | 2022 | 177 | 0.050 |
Why?
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 71 | 0.050 |
Why?
| Drug Therapy, Combination | 3 | 2016 | 965 | 0.050 |
Why?
| Random Allocation | 3 | 2006 | 344 | 0.050 |
Why?
| gamma-Aminobutyric Acid | 1 | 2001 | 155 | 0.050 |
Why?
| Heart Failure | 1 | 2013 | 1969 | 0.050 |
Why?
| Ligands | 2 | 2012 | 567 | 0.050 |
Why?
| Phenotype | 3 | 2016 | 3003 | 0.050 |
Why?
| Hematinics | 1 | 2019 | 17 | 0.040 |
Why?
| Astrocytoma | 1 | 2020 | 113 | 0.040 |
Why?
| Tunica Intima | 1 | 2000 | 78 | 0.040 |
Why?
| Brain Stem Neoplasms | 1 | 2020 | 90 | 0.040 |
Why?
| Pregnancy Complications | 1 | 2004 | 448 | 0.040 |
Why?
| Cell Movement | 2 | 2015 | 896 | 0.040 |
Why?
| Knee Joint | 1 | 2022 | 353 | 0.040 |
Why?
| Sheep, Domestic | 1 | 2019 | 32 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 333 | 0.040 |
Why?
| Fluorescent Antibody Technique | 2 | 2013 | 410 | 0.040 |
Why?
| Mouth Mucosa | 1 | 2019 | 82 | 0.040 |
Why?
| Radiology, Interventional | 1 | 2019 | 28 | 0.040 |
Why?
| Enzyme Activation | 2 | 2013 | 828 | 0.040 |
Why?
| Chromatography, Liquid | 1 | 2000 | 355 | 0.040 |
Why?
| Drug Administration Schedule | 2 | 2013 | 736 | 0.040 |
Why?
| Lysine | 1 | 2020 | 248 | 0.040 |
Why?
| Survival Analysis | 2 | 2016 | 1267 | 0.040 |
Why?
| Mifepristone | 1 | 2018 | 65 | 0.040 |
Why?
| Carcinoma, Adenoid Cystic | 1 | 2018 | 18 | 0.040 |
Why?
| Transplantation, Homologous | 1 | 2000 | 415 | 0.040 |
Why?
| Anthropometry | 1 | 2019 | 194 | 0.040 |
Why?
| Salivary Glands | 1 | 2018 | 32 | 0.040 |
Why?
| Breast | 1 | 2019 | 140 | 0.040 |
Why?
| Amino Acids | 1 | 2002 | 465 | 0.040 |
Why?
| Phantoms, Imaging | 1 | 2019 | 139 | 0.040 |
Why?
| NF-kappa B | 2 | 2013 | 670 | 0.040 |
Why?
| Citric Acid Cycle | 1 | 1997 | 45 | 0.040 |
Why?
| Child | 3 | 2023 | 19129 | 0.040 |
Why?
| Weight Gain | 1 | 2001 | 493 | 0.040 |
Why?
| Cell Size | 1 | 1997 | 86 | 0.040 |
Why?
| Lung Neoplasms | 1 | 2010 | 2220 | 0.040 |
Why?
| Immunohistochemistry | 2 | 2012 | 1691 | 0.040 |
Why?
| Digoxin | 1 | 2017 | 27 | 0.040 |
Why?
| Robotics | 1 | 2019 | 83 | 0.040 |
Why?
| Pentose Phosphate Pathway | 1 | 2017 | 44 | 0.040 |
Why?
| Aorta | 1 | 2000 | 367 | 0.040 |
Why?
| Cysteine | 1 | 2018 | 184 | 0.040 |
Why?
| Cytosol | 1 | 1997 | 221 | 0.040 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2010 | 67 | 0.040 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2019 | 220 | 0.040 |
Why?
| Diet, High-Fat | 1 | 2018 | 247 | 0.040 |
Why?
| Nanomedicine | 1 | 2017 | 28 | 0.040 |
Why?
| Benzothiazoles | 1 | 2016 | 37 | 0.040 |
Why?
| Hydrazines | 1 | 2016 | 31 | 0.040 |
Why?
| Rabbits | 1 | 2018 | 780 | 0.040 |
Why?
| Lymph Nodes | 1 | 2019 | 455 | 0.040 |
Why?
| Adventitia | 1 | 2016 | 39 | 0.040 |
Why?
| Heat Shock Transcription Factors | 2 | 2006 | 17 | 0.040 |
Why?
| Carbon | 1 | 2017 | 170 | 0.030 |
Why?
| Gestational Age | 1 | 2019 | 765 | 0.030 |
Why?
| Phenylurea Compounds | 1 | 2016 | 85 | 0.030 |
Why?
| Membrane Lipids | 1 | 1996 | 88 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 539 | 0.030 |
Why?
| Fatty Acid Transport Proteins | 1 | 2015 | 18 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2016 | 220 | 0.030 |
Why?
| Epoxy Compounds | 1 | 2015 | 33 | 0.030 |
Why?
| Transforming Growth Factor beta | 1 | 2018 | 462 | 0.030 |
Why?
| Stem Cell Niche | 1 | 2015 | 43 | 0.030 |
Why?
| Animals, Newborn | 1 | 1997 | 806 | 0.030 |
Why?
| Risk Factors | 1 | 2009 | 9000 | 0.030 |
Why?
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2015 | 47 | 0.030 |
Why?
| Sodium Hydroxide | 1 | 2014 | 8 | 0.030 |
Why?
| Neoplasm Recurrence, Local | 1 | 2020 | 900 | 0.030 |
Why?
| Lipoprotein Lipase | 1 | 2015 | 68 | 0.030 |
Why?
| Precision Medicine | 1 | 2019 | 363 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 56 | 0.030 |
Why?
| Half-Life | 1 | 2014 | 147 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2015 | 311 | 0.030 |
Why?
| Recovery of Function | 1 | 2018 | 604 | 0.030 |
Why?
| Software | 1 | 2019 | 613 | 0.030 |
Why?
| Radiopharmaceuticals | 1 | 2015 | 194 | 0.030 |
Why?
| Pyrroles | 1 | 2015 | 191 | 0.030 |
Why?
| Bone Marrow | 1 | 2015 | 255 | 0.030 |
Why?
| Superoxides | 1 | 2014 | 221 | 0.030 |
Why?
| Maze Learning | 1 | 2014 | 86 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2015 | 462 | 0.030 |
Why?
| Tissue Donors | 2 | 2010 | 336 | 0.030 |
Why?
| Mice, Mutant Strains | 1 | 2014 | 280 | 0.030 |
Why?
| Enzyme Induction | 1 | 2013 | 94 | 0.030 |
Why?
| Breeding | 1 | 2013 | 56 | 0.030 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2014 | 190 | 0.030 |
Why?
| beta-Galactosidase | 1 | 2013 | 65 | 0.030 |
Why?
| Mice, Inbred A | 1 | 2013 | 45 | 0.030 |
Why?
| Amino Acids, Aromatic | 1 | 2013 | 7 | 0.030 |
Why?
| Particle Size | 1 | 2014 | 345 | 0.030 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2013 | 69 | 0.030 |
Why?
| Catalysis | 1 | 2014 | 295 | 0.030 |
Why?
| Transcriptome | 1 | 2019 | 756 | 0.030 |
Why?
| Vacuoles | 1 | 2013 | 33 | 0.030 |
Why?
| Somatomedins | 1 | 2013 | 27 | 0.030 |
Why?
| Cell Differentiation | 1 | 2020 | 1753 | 0.030 |
Why?
| Staining and Labeling | 1 | 2013 | 146 | 0.030 |
Why?
| Keratins | 1 | 2013 | 174 | 0.030 |
Why?
| Hyperplasia | 1 | 2013 | 170 | 0.030 |
Why?
| Mitogens | 1 | 2013 | 57 | 0.030 |
Why?
| Cell Shape | 1 | 2013 | 57 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2013 | 195 | 0.030 |
Why?
| Glucose Transporter Type 4 | 1 | 2012 | 38 | 0.030 |
Why?
| Mitochondrial Proteins | 1 | 2014 | 226 | 0.030 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 80 | 0.030 |
Why?
| RNA Interference | 1 | 2014 | 460 | 0.030 |
Why?
| Adenoviridae | 1 | 2013 | 191 | 0.030 |
Why?
| RNA, Messenger | 2 | 2013 | 2657 | 0.030 |
Why?
| Integrases | 1 | 2013 | 123 | 0.030 |
Why?
| Carcinogens | 1 | 2013 | 108 | 0.030 |
Why?
| Transplantation, Heterologous | 1 | 2013 | 194 | 0.030 |
Why?
| Neoplasm Grading | 1 | 2013 | 258 | 0.030 |
Why?
| Long-Term Potentiation | 1 | 2014 | 148 | 0.030 |
Why?
| Epidermal Growth Factor | 1 | 2013 | 173 | 0.030 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 160 | 0.030 |
Why?
| Estradiol | 1 | 2015 | 476 | 0.030 |
Why?
| Molecular Chaperones | 1 | 2013 | 174 | 0.030 |
Why?
| RNA, Untranslated | 1 | 2013 | 115 | 0.030 |
Why?
| Colorado | 1 | 2022 | 4196 | 0.030 |
Why?
| Decision Making | 1 | 2019 | 809 | 0.030 |
Why?
| Mice, Inbred MRL lpr | 1 | 2011 | 39 | 0.030 |
Why?
| Gene Regulatory Networks | 1 | 2013 | 239 | 0.030 |
Why?
| Sucrose | 1 | 2012 | 104 | 0.030 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2013 | 298 | 0.030 |
Why?
| Self Administration | 1 | 2012 | 125 | 0.030 |
Why?
| Bortezomib | 1 | 2011 | 42 | 0.020 |
Why?
| beta Catenin | 1 | 2013 | 219 | 0.020 |
Why?
| Adenine | 1 | 2013 | 223 | 0.020 |
Why?
| Fatigue | 1 | 2013 | 297 | 0.020 |
Why?
| Nestin | 1 | 2010 | 16 | 0.020 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 202 | 0.020 |
Why?
| Urethane | 1 | 2010 | 41 | 0.020 |
Why?
| Kidney Glomerulus | 1 | 2011 | 133 | 0.020 |
Why?
| Protein Biosynthesis | 1 | 2013 | 397 | 0.020 |
Why?
| Intermediate Filament Proteins | 1 | 2010 | 69 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 770 | 0.020 |
Why?
| Neutrophils | 2 | 2006 | 1233 | 0.020 |
Why?
| Receptors, Complement 3d | 1 | 2011 | 129 | 0.020 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2011 | 139 | 0.020 |
Why?
| Mesenteric Arteries | 1 | 2010 | 16 | 0.020 |
Why?
| Immunoblotting | 1 | 2011 | 307 | 0.020 |
Why?
| HT29 Cells | 1 | 2010 | 37 | 0.020 |
Why?
| Kidney Function Tests | 1 | 2010 | 164 | 0.020 |
Why?
| Cluster Analysis | 1 | 2011 | 481 | 0.020 |
Why?
| Hydrogen | 1 | 2010 | 65 | 0.020 |
Why?
| Caspase 3 | 1 | 2011 | 243 | 0.020 |
Why?
| Limit of Detection | 1 | 2009 | 55 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2010 | 108 | 0.020 |
Why?
| Capillary Permeability | 1 | 2010 | 140 | 0.020 |
Why?
| Transplantation Conditioning | 1 | 2010 | 156 | 0.020 |
Why?
| Constriction, Pathologic | 1 | 2010 | 203 | 0.020 |
Why?
| Aged, 80 and over | 2 | 2013 | 6561 | 0.020 |
Why?
| Portal Vein | 1 | 2010 | 90 | 0.020 |
Why?
| Hippocampus | 1 | 2014 | 735 | 0.020 |
Why?
| Citrates | 1 | 2009 | 48 | 0.020 |
Why?
| Gene Deletion | 1 | 2010 | 361 | 0.020 |
Why?
| Celecoxib | 1 | 2008 | 38 | 0.020 |
Why?
| STAT3 Transcription Factor | 1 | 2010 | 189 | 0.020 |
Why?
| Capecitabine | 1 | 2008 | 46 | 0.020 |
Why?
| Cell Cycle | 1 | 2011 | 550 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2010 | 380 | 0.020 |
Why?
| Free Radicals | 1 | 2009 | 104 | 0.020 |
Why?
| Dura Mater | 1 | 2008 | 29 | 0.020 |
Why?
| Mammary Tumor Virus, Mouse | 1 | 2008 | 41 | 0.020 |
Why?
| Principal Component Analysis | 1 | 2009 | 180 | 0.020 |
Why?
| Mammary Neoplasms, Animal | 1 | 2008 | 29 | 0.020 |
Why?
| Craniotomy | 1 | 2008 | 69 | 0.020 |
Why?
| Down-Regulation | 1 | 2010 | 627 | 0.020 |
Why?
| Bronchoscopy | 2 | 2000 | 247 | 0.020 |
Why?
| Genotype | 1 | 2013 | 1882 | 0.020 |
Why?
| Drug Discovery | 1 | 2009 | 124 | 0.020 |
Why?
| Pressure | 1 | 2008 | 226 | 0.020 |
Why?
| Hypoglycemic Agents | 1 | 2015 | 1032 | 0.020 |
Why?
| Ethanol | 1 | 2012 | 575 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2013 | 1323 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2010 | 527 | 0.020 |
Why?
| Nerve Tissue Proteins | 1 | 2010 | 551 | 0.020 |
Why?
| Carcinoma | 1 | 2008 | 204 | 0.020 |
Why?
| Child, Preschool | 1 | 2020 | 9491 | 0.020 |
Why?
| Peroxidase | 1 | 2006 | 170 | 0.020 |
Why?
| Aspartate Aminotransferases | 1 | 2006 | 95 | 0.020 |
Why?
| Intensive Care Units | 1 | 2010 | 635 | 0.020 |
Why?
| Risk | 1 | 2008 | 853 | 0.020 |
Why?
| Pilot Projects | 1 | 2010 | 1419 | 0.020 |
Why?
| Alanine Transaminase | 1 | 2006 | 152 | 0.020 |
Why?
| Membrane Transport Proteins | 1 | 2006 | 137 | 0.020 |
Why?
| Organ Size | 1 | 2006 | 460 | 0.020 |
Why?
| Case-Control Studies | 1 | 2013 | 3171 | 0.020 |
Why?
| HSP27 Heat-Shock Proteins | 1 | 2005 | 14 | 0.020 |
Why?
| Intestinal Mucosa | 1 | 2010 | 531 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 667 | 0.020 |
Why?
| Quercetin | 1 | 2005 | 12 | 0.020 |
Why?
| Cerebral Cortex | 1 | 2008 | 416 | 0.020 |
Why?
| Cytokines | 1 | 2013 | 1900 | 0.020 |
Why?
| Computational Biology | 1 | 2009 | 588 | 0.020 |
Why?
| Dietary Fats | 1 | 2006 | 322 | 0.020 |
Why?
| Transplantation, Isogeneic | 1 | 2003 | 17 | 0.020 |
Why?
| Raffinose | 1 | 2003 | 20 | 0.020 |
Why?
| Organ Preservation Solutions | 1 | 2003 | 44 | 0.010 |
Why?
| Allopurinol | 1 | 2003 | 82 | 0.010 |
Why?
| Transcriptional Activation | 1 | 2005 | 348 | 0.010 |
Why?
| Protein Binding | 1 | 2009 | 1975 | 0.010 |
Why?
| Cell Membrane | 1 | 2006 | 710 | 0.010 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2004 | 219 | 0.010 |
Why?
| Adenosine | 1 | 2003 | 211 | 0.010 |
Why?
| Preoperative Care | 1 | 2004 | 332 | 0.010 |
Why?
| Trans-Activators | 1 | 2004 | 373 | 0.010 |
Why?
| Lipopolysaccharides | 1 | 2005 | 870 | 0.010 |
Why?
| Gene Expression | 1 | 2006 | 1489 | 0.010 |
Why?
| Automation | 1 | 2000 | 77 | 0.010 |
Why?
| Microchemistry | 1 | 2000 | 15 | 0.010 |
Why?
| Calibration | 1 | 2000 | 135 | 0.010 |
Why?
| Receptors, Interleukin-2 | 1 | 2000 | 65 | 0.010 |
Why?
| Emulsions | 1 | 2000 | 45 | 0.010 |
Why?
| Autopsy | 1 | 2000 | 89 | 0.010 |
Why?
| Blood | 1 | 2000 | 100 | 0.010 |
Why?
| Postoperative Period | 1 | 2000 | 309 | 0.010 |
Why?
| Prospective Studies | 1 | 2010 | 6471 | 0.010 |
Why?
| Chronic Disease | 1 | 2004 | 1636 | 0.010 |
Why?
| Immune Tolerance | 1 | 2000 | 334 | 0.010 |
Why?
| Regression Analysis | 1 | 2000 | 983 | 0.010 |
Why?
| Recombinant Fusion Proteins | 1 | 2000 | 653 | 0.010 |
Why?
| Biopsy | 1 | 2000 | 1079 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 2000 | 1795 | 0.010 |
Why?
|
|
Serkova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|